Compound Summary
Compound Information
zalcitabine
Compound Name: | zalcitabine |
Compound CID: | 24066 |
Synonyms: | zalcitabine Dideoxycytidine 7481-89-2 2,3-DIDEOXYCYTIDINE ddCyd More... |
Iupac Name: | 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
InChI: | InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1 |
InChIKey: | WREGKURFCTUGRC-POYBYMJQSA-N |
Canonical Smiles: | C1CC(OC1CO)N2C=CC(=NC2=O)N |
Isomeric Smiles: | C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N |
Molecular Weight: | 211.22 |
Molecular Formula: | C9H13N3O3 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
zalcitabine
Molecular Weight: | 211.22 |
Molecular Formula: | C9H13N3O3 |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 3 |
Rotatable Bond Count: | 2 |
Heavy Atom Count: | 15 |
Complexity: | 327 |
Synonyms
zalcitabine
| zalcitabine | zalcitabine |
|---|---|
zalcitabine |
Dideoxycytidine |
7481-89-2 |
2,3-DIDEOXYCYTIDINE |
ddCyd |
HIVID |
Cytidine, 2,3-dideoxy- |
ddC |
Zalcitibine |
4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one |
NSC 606170 |
Ro 24-2027/000 |
UNII-6L3XT8CB3I |
CHEMBL853 |
6L3XT8CB3I |
4-amino-1-(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-ylpyrimidin-2(1H)-one |
CHEBI:10101 |
MFCD00012188 |
NCGC00090705-08 |
DSSTox_CID_3747 |
NSC-606170 |
4-AMINO-1-(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL-1,2-DIHYDROPYRIMIDIN-2-ONE |
DSSTox_RID_77182 |
DSSTox_GSID_23747 |
2,3-dideoxycytidine |
NSC606170 |
4-amino-1-(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-ylpyrimidin-2-one |
SMR000058253 |
CCRIS 692 |
Hivid(TM) |
Hivid (TN) |
HSDB 7156 |
Interferon AD + ddC |
ddC & GM-CSF |
ddC & sCD4 |
PC-SOD & ddC |
Ro-24-2027/000 |
DDC (DDC) |
BRN 0654956 |
Zalcitabine (JAN/USP/INN) |
DS-4152 & ddC |
3-(5S,2R)-5-(hydroxymethyl)oxolan-2-yl-6-amino-3-hydropyrimidin-2-one |
1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine |
ddC & NP (from PHCA or HSA) |
SRI-7707 |
Zalcitabine USAN:USP:INN:BAN |
CAS-7481-89-2 |
Zalcitabine- Bio-X |
KS-1130 |
ddC & IFN.alpha. |
.beta.-D-DDC |
dideoxycytidine (DDC) |
4-amino-1-(2R,5S)-5-(hydroxymethyl)oxolan-2-ylpyrimidin-2-one |
Prestwick0_001037 |
Prestwick1_001037 |
Prestwick2_001037 |
Prestwick3_001037 |
ddC & Interferon.alpha. |
2, 3-dideoxycytidine |
bmse000712 |
UPCMLD-DP115 |
D 5782 |
SCHEMBL3598 |
TimTec1_004969 |
Lopac0_000360 |
BSPBio_001253 |
3-Azido-3-deoxythymidine/2,3-Dideoxycytidine |
5-25-14-00313 (Beilstein Handbook Reference) |
MLS000069636 |
MLS000759540 |
MLS001055363 |
MLS001424210 |
MLS006011951 |
SPBio_003104 |
BPBio1_001378 |
GTPL4828 |
ddC|||2,3-Dideoxycytidine |
DTXSID0023747 |
UPCMLD-DP115:001 |
ZINC39906 |
2,3-Dideoxycytidine & sCD4(soluble recombinant protein) |
AOB5609 |
HMS1548B19 |
HMS1571O15 |
HMS2051H18 |
HMS2090C12 |
HMS2098O15 |
HMS2236N08 |
HMS3261G21 |
HMS3715O15 |
Pharmakon1600-01502360 |
.beta.-D-2,3-Dideoxycytidine" |
Zalcitabine, 23-Dideoxycytidine |
BCP13878 |
Tox21_113491 |
Tox21_201655 |
Tox21_303169 |
Tox21_500360 |
AC-824 |
BDBM50145605 |
Lecithinized superoxide dismutase & .beta.-D-2,3-Dideoxycytidine |
NSC759655 |
s1719 |
SBB066036 |
Sulfated polysaccharide-peptidoglycan DS-4152 & 2,3-Dideoxycytidine |
AKOS015854844 |
AKOS015894505 |
Tox21_113491_1 |
CCG-101050 |
CS-1110 |
DB00943 |
LP00360 |
MCULE-6071296177 |
NC00300 |
NSC-759655 |
SDCCGSBI-0050348.P002 |
2,3-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate) |
SRI-7707-13 |
SRI-7707-14 |
SRI-7707_15 |
SRI-7707_17 |
NCGC00090705-01 |
NCGC00090705-02 |
NCGC00090705-03 |
NCGC00090705-05 |
NCGC00090705-06 |
NCGC00090705-07 |
NCGC00090705-09 |
NCGC00090705-10 |
NCGC00090705-11 |
NCGC00090705-13 |
NCGC00090705-15 |
NCGC00090705-24 |
NCGC00090705-25 |
NCGC00179242-01 |
NCGC00257202-01 |
NCGC00259204-01 |
NCGC00261045-01 |
BD164564 |
HY-17392 |
K278 |
ST069364 |
ddC;Dideoxycytidine;2,3-Dideoxycytidine" |
2,3-Dideoxycytidine & Interferon.alpha." |
2,3-Dideoxycytidine, >=98% (HPLC) |
AB0014137 |
DB-019728 |
Ro-242027000 |
D3581 |
EU-0100360 |
Ro-24-2027000 |
SW197364-4 |
2,3-Dideoxycytidine, >=99.0% (HPLC) |
C07207 |
C76390 |
D00412 |
42060-EP2295503A1 |
42060-EP2298761A1 |
42060-EP2305695A2 |
42060-EP2305696A2 |
42060-EP2305697A2 |
42060-EP2305698A2 |
42060-EP2311808A1 |
42060-EP2311829A1 |
78798-EP2298783A1 |
78798-EP2305695A2 |
78798-EP2305696A2 |
78798-EP2305697A2 |
78798-EP2305698A2 |
Cytidine, 2,3-dideoxy- & Interferon.alpha. |
481D892 |
A838234 |
SR-01000075822 |
SR-01000736919 |
J-700276 |
Q-201941 |
Q2344582 |
SR-01000075822-1 |
SR-01000736919-5 |
Cytidine, 2,3-dideoxy- & Colony-stimulating factor |
Ro-242027000/Ro-24-2027-000 |
Z1550648753 |
Zalcitabine, United States Pharmacopeia (USP) Reference Standard |
4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one |
.beta.-D-2,3-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor" |
Experimental Data
zalcitabine
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | 10 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
zalcitabine
Statistics Data
zalcitabine
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 10 | 1 | 1 |
Statistics Data Visualization
zalcitabine
